<DOC>
	<DOCNO>NCT02131415</DOCNO>
	<brief_summary>This non-interventional , Canadian , study patient treat Abilify Maintena™ schizophrenia follow 24 month , 9 visit recommend . Study assessments administration questionnaire take place patient regular assessment injection visit part routine care . The main objective study describe impact treatment Abilify Maintena™ global functional status .</brief_summary>
	<brief_title>Real Life Assessment Abilify Maintena</brief_title>
	<detailed_description>- Treatment - All patient treat Abilify Maintena™ administer monthly dose per treat physician 's judgment . - The assignment patient treat Abilify Maintena™ decide advance study protocol clearly separate decision include patient study . For patient include study , decision initiate treatment Abilify Maintena™ must reach prior independently enrol patient study . - Any treatment prescribe accord recommendation give approve Canadian Product Monograph . - Study Sites - Up 30 site plan Canada : Patients recruit community hospital base psychiatrist . A random representative sample Canadian psychiatrist identify sampled population physician invite participate study undergo feasibility assessment . Those satisfy feasibility assessment , adequate volume patient willing participate study enrol . - Data Collection Handling - All patient data collect site investigator designated staff enter electronic data capture ( EDC ) system develop study . Patient questionnaire complete visit use paper-based survey . The questionnaire data transcribe study database CRO personnel use double data entry system . There patient identifying information record study data collection form database . All patient identify use encrypted random study ID number . Data monitoring source verification conduct sample patient . Auditing patient qualification also conduct sample patient within site . - Missing data handle - There imputation miss data . General linear model repeat measure mixed effect use compensate unequal follow interval miss data point . All analysis conduct observed case . - Safety analyse - The safety population comprise patient include study least one treatment Abilify Maintena™ . Adverse event describe MedDRA dictionary term classify preferred term system - organ class .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Inclusion Criteria The patient must 18 ( 19 patient British Columbia ) year age old . The patient must diagnose schizophrenia . The patient must least mildly ill ( CGIS score ≥3 ) . The treat physician must reach decision treat patient Abilify Maintena™ prior independently solicit patient participate study . The patient legal guardian ( applicable allowable law ) must sign informed consent indicate understand study allow use anonymous data purpose study . The patient caregiver ( ) ( applicable ) must fluent English French , order able complete questionnaire . Exclusion Criteria The patient comprehend refuse sign informed consent . The patient contraindication use Abilify Maintena™ specify Canadian Product Monograph . The patient previously receive one dos Abilify Maintena™ . The patient present significant suicidal risk judge investigator . The patient pregnant lactate female . The patient member study personnel immediate family , subordinate ( immediate family member subordinate ) study personnel . The patient previously enrol study . The patient , investigator 's opinion , unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>real-life</keyword>
	<keyword>long-acting injectable</keyword>
	<keyword>Reliam</keyword>
</DOC>